Jupiter Topco LLC Invests $266.63 Million in Dyne Therapeutics, Inc. $DYN

Jupiter Topco LLC purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,997,738 shares of the company’s stock, valued at approximately $266,634,000. Jupiter Topco LLC owned 0.06% of Dyne Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Hilton Head Capital Partners LLC bought a new stake in shares of Dyne Therapeutics during the 1st quarter worth approximately $26,000. Strs Ohio bought a new stake in Dyne Therapeutics during the fourth quarter worth $51,000. Allworth Financial LP acquired a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at $62,000. Aster Capital Management DIFC Ltd bought a new position in shares of Dyne Therapeutics in the 4th quarter valued at $84,000. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Up 1.3%

Shares of DYN opened at $26.34 on Wednesday. The stock’s 50-day moving average price is $23.99 and its two-hundred day moving average price is $19.89. Dyne Therapeutics, Inc. has a 12 month low of $11.92 and a 12 month high of $27.31. The company has a market capitalization of $4.92 billion, a PE ratio of -7.91 and a beta of 1.07. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 EPS for the current year.

Analyst Ratings Changes

DYN has been the subject of several recent analyst reports. Sanford C. Bernstein upped their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. TD Cowen started coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating on the stock. Morgan Stanley lowered their price objective on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.42.

Insider Buying and Selling

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the transaction, the chief financial officer owned 121,563 shares in the company, valued at approximately $2,476,238.31. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares in the company, valued at $10,723,650. This trade represents a 83.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,139,196 shares of company stock valued at $99,449,852 in the last three months. Insiders own 9.46% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.